JYMed is pleased to announce that the U.S. Food and Drug Administration has acknowledged receipt of a new Type II Drug Master File for semaglutide API manufactured under a new process. FDA acknowledgment letter for JYMed’s Type II DMF filing for semaglutide API...
A condition may be “rare,” but no person should feel invisible.At JY MedTech, we recognize the resilience of the rare disease community and the importance of continued collaboration across science and healthcare.Today, we stand with patients, families, advocates, and...
From all of us at JYMed Peptide, we wish our customers, partners, and friends around the world a joyful Lunar New Year, filled with good health, happiness, and success. Thank you for your continued trust and collaboration. We look forward to supporting your projects...
As part of our semaglutide program, JY MedTech has successfully completed the registration of the semaglutide active pharmaceutical ingredient (API) Korean Drug Master File (K-DMF) in South Korea. The API registration certificate has been issued by the Korean Ministry...
JYMed Peptide has been independently assessed by EcoVadis Bronze Medal Dec 2025, a globally recognized sustainability ratings provider used across supply chains. In the December 2025 assessment, JYMed Peptide achieved an overall score of 70/100, placing us in the 83rd...
中文
